拉坦前列素在儿童青光眼及高眼压患者中的长期安全性研究
这项前瞻性队列研究在欧美14国纳入175例<18岁青光眼或高眼压患者,比较拉坦前列素与非前列腺素类治疗对眼发育和安全性的长期影响。3年随访显示两组最佳矫正视力变化、角膜厚度及眼部色素沉着均无统计学显著差异。
要点
- 拉坦前列素组与非PG组3年BCVA变化无统计学显著差异。
- 两组角膜厚度及眼部色素沉着均无统计学显著差异。
- 拉坦前列素在儿童青光眼/高眼压患者中安全性可接受。
核心结论
- 拉坦前列素在儿童青光眼及高眼压患者中具有可接受的安全性,未发现诱导临床意义或统计学显著的眼发育或眼部色素沉着改变的证据。
研究设计与样本
- 前瞻性3年队列研究,在欧洲和南美洲14个国家开展,纳入<18岁青光眼或高眼压患者,分为拉坦前列素组与非前列腺素(non-PG)组进行观察。
- 共纳入175例患者:拉坦前列素组102例(中位随访36.7个月),非PG组73例(中位随访36.1个月)。
- 主要终点为基线至3年最佳矫正视力(BCVA)变化;次要终点包括角膜厚度和眼部色素沉着。
主要发现
- 拉坦前列素组与非PG组(5至<18岁)在BCVA基线变化上无统计学显著差异,最小二乘均值logMAR差异为-0.03(95%CI:-0.12,0.06)。
- 两组在角膜厚度和眼部色素沉着方面无统计学显著差异。
关键数值与推荐
- 连续终点采用协方差分析(ANCOVA),临床显著恶化事件比例采用Fisher精确检验。
- BCVA变化的最小二乘均值logMAR差异为-0.03(95%CI:-0.12,0.06)。
临床怎么用
- 为儿童青光眼及高眼压患者长期使用拉坦前列素的安全性提供了前瞻性队列证据,支持在密切监测下使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The objective was to assess the long-term effect of treatment with latanoprost on ocular development and safety in pediatric patients with glaucoma and ocular hypertension. DESIGN: Prospective cohort study. METHODS: This was a prospective 3-year cohort study conducted in 14 countries in Europe and South America. Patients aged < 18 years with glaucoma or ocular hypertension were enrolled into either the latanoprost or non-prostaglandin (non-PG) group in this observational study. The primary endpoint was change in best-corrected visual acuity (BCVA) from baseline to 3 years. Several secondary endpoints were evaluated, including corneal thickness and ocular hyperpigmentation. For treatment comparison, analysis of covariance (ANCOVA) was used for continuous endpoints and Fisher exact test was applied for proportion of participants with clinically significant deterioration events. RESULTS: A total of 175 patients were enrolled: 102 in the latanoprost group (median follow-up: 36.7 months) and 73 in the non-PG group (median follow-up: 36.1 months). There was no statistically significant difference between the latanoprost and the non-PG groups (aged 5 to <18 years) in BCVA change from baseline (least square mean logMAR difference -0.03 [95% confidence interval: -0.12, 0.06]), corneal thickness, or ocular hyperpigmentation. CONCLUSIONS: Latanoprost had an acceptable safety profile with no evidence of inducing clinically meaningful or statistically significant changes in ocular development or ocular hyperpigmentation in pediatric patients with glaucoma and ocular hypertension.
引用
- Younus M, Schachar RA, Zhang M, et al. A Long-term Safety Study of Latanoprost in Pediatric Patients With Glaucoma and Ocular Hypertension: A Prospective Cohort Study. Am J Ophthalmol. 2018. PMID: 30194929. doi:10.1016/j.ajo.2018.08.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。